Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2018 / Feb / Super Saliva Test
Microbiology & Immunology Microbiology and Immunology Microbiology and Immunology Screening and monitoring

Super Saliva Test

Ultrasensitive PCR powers an oral fluid assay for earlier HIV diagnosis

By William Aryitey 02/23/2018 1 min read

Share

The advent of antiretroviral therapies to control HIV and the use of pre-exposure prophylaxis has turned a once-terminal illness into a relatively manageable disease when caught early enough. But although great strides have been made to curb the virus, 36.7 million people worldwide currently live with HIV – nearly half of whom are unsure of the status of their infection (1). Clearly, without access to adequate testing, it’s difficult for both patients and the medical community to keep track. And that’s why Carolyn Bertozzi and her team decided to develop a highly sensitive HIV assay for saliva (2). At the moment, there are two main types of tests for screening HIV, each with pros and cons: blood tests are highly sensitive, but have a poor rate of compliance despite being minimally invasive; oral fluid tests, on the other hand, although noninvasive, typically suffer from poor sensitivity because of the lower concentrations of anti-HIV antibodies. The new oral fluid assay addresses the challenge by using antibody detection by agglutination-PCR (ADAP) – making it 1,000–10,000 times more sensitive than existing tests. “ADAP is based on the concept of proximity ligation PCR, which we knew had the capability of ultrasensitive DNA detection. This ADAP was designed to bring the sensitivity of PCR to the problem of antibody detection,” says Bertozzi, lead investigator, and Anne T. and Robert M. Bass Professor of Chemistry at Stanford University. “The ADAP test can enable earlier detection of HIV infection in the context of population screening using oral fluid, which is easier to collect and far less risky for healthcare workers because, unlike blood, oral fluid is not infectious.”

Bertozzi acknowledges that translating the research to the clinic is no small feat: “The biggest hurdles that lie ahead are larger studies with longitudinal data to judge how ADAP compares with current oral and blood-based tests.” But the team also see great promise in the ADAP assays, and plan to develop analogous tests for other infectious and autoimmune diseases that produce autoantibody biomarkers.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. HIV.gov, “The global HIV/AIDS epidemic” (2017). Available at: http://bit.ly/2xpEQnn. Accessed February 1, 2018. CT Tsai et al., “Antibody detection by agglutination-PCR (ADAP) enables early diagnosis of HIV infection by oral fluid analysis”, Proc Natl Acad Sci USA, [Epub ahead of print] (2018). PMID: 29358368.

About the Author(s)

William Aryitey

My fascination with science, gaming, and writing led to my studying biology at university, while simultaneously working as an online games journalist. After university, I travelled across Europe, working on a novel and developing a game, before finding my way to Texere. As Associate Editor, I’m evolving my loves of science and writing, while continuing to pursue my passion for gaming and creative writing in a personal capacity.

More Articles by William Aryitey

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Context Matters in Cancer Biology
Microbiology and Immunology
Context Matters in Cancer Biology

December 27, 2021

1 min read

Akoya is leading the way with spatial phenotypic signatures – a novel class of biomarkers for predicting response to immunotherapy

What’s New in Infectious Disease? (December 2021)
Microbiology and Immunology
What’s New in Infectious Disease?

December 23, 2021

1 min read

The latest research and news on COVID-19 and the infectious disease landscape

Immunology Insights
Microbiology and Immunology
Immunology Insights

January 13, 2022

1 min read

The latest research in pathology and laboratory medicine

2021: A Laboratory Medicine Roundup
Microbiology and Immunology
2021: A Laboratory Medicine Roundup

January 18, 2022

3 min read

From transgender health care to the power of pathology podcasts, we take a look at our most popular articles of the last year

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.